Supplier Qualification and Oversight in an FDA Warning Letter
FDA's Center for Drug Evaluation and Research (CDER) issued a Warning Letter to Nanjing Hanxin Pharmaceutical Technology Co. Ltd., a registered manufacturer of active pharmaceutical ingredients (APIs). The letter shows how a qualification failure at one link in the supply chain can end in import restrictions for the whole chain.
What the FDA found
The FDA's review of records found that Nanjing Hanxin's quality unit "failed to adequately qualify [...] suppliers of critical raw materials". The company had qualified a supplier of a critical starting material, however that supplier was placed on Import Alert 66-40. FDA's conclusion was blunt: "Your oversight of your suppliers is deficient".
The FDA also wrote that naming Nanjing Hanxin rather than the actual manufacturer "may have been an attempt to circumvent safeguards" and may pose a risk of substandard APIs. On 22 June 2026, FDA placed all drugs offered for import also on Import Alert 66-40.
Why this matters for every GMP Operation
- Qualification must reach the real manufacturer: A supplier's paperwork is not enough. Map the full origin of each critical starting material, including sub-tier sites and any relocated production.
- The quality unit needs real authority: FDA expects a remediation plan that gives the quality unit "the authority and resources to effectively function," including review of each lot before disposition
- Traceability must be complete: The FDA requested a list of all drugs distributed in the last three years, with the original supplier or starting-material source, and written notice to customers for affected lots.
- Transparency is not optional: Identifying the true manufacturer is central to the trust that supplier qualification depends on.
Related GMP News
18.11.2026Warning Letter - Endotoxins, Microbiological Weaknesses and Further Contamination
11.11.2026FDA Updates how it Evaluates and Inspects Human Drug Facilities
11.11.2026FDA Warning Letter to US based Manufacturer: Sterile Manufacturing Failures
28.10.2026Inadequate Supplier Oversight and missing Tests: Lessons from an FDA Warning Letter


